Effects of tolvaptan in congestive heart failure patients with renal dysfunction

Effects of tolvaptan in congestive heart failure patients with renal dysfunction - Effects of tolvaptan in congestive heart failure patients with renal dysfunction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005465

Enrollment

200

Registered

2011-04-25

Start date

2011-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

congestive heart failure

Interventions

14 days administration of tolvaptan with reducing loop diuretis to half 14 days administration of tolvaptan without changing loop diuretis

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Congestive heart failure patients with renal dysfunction(Cre>=1.1 mg/dL) in hospital

Exclusion criteria

Exclusion criteria: 1) Patients who a history of hypersensitivity to tolvaptan 2) Patients with severe hypotention or cardioganic shock 3) Patients with cardiac assist device 4) Patients with dehydration 5) Patients with systolic blood pressure < 90mmHg 6) Patients with serum Na > 147 mEq/L or serum K > 5.5 mEq/L or T- bilirubin > 3.0 mg/dL 7)Patients considered not eligible for the study by the attending doctor due to other reasons

Design outcomes

Primary

Measure	Time frame
The rate of change of serum creatinine	—

Secondary

Measure	Time frame
body weight, daily urine volume, congestive findings(leg edema, jugular vein dilatation, pulmonary congestion ), serum sodium, serum potassium, cystatin C	—

Countries

Japan

Contacts

Public ContactAkihisa Hanatani

Osaka city university graduate school of medicine Department of cardiology

06-6645-3801

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026